MedTrace Logo

Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder

NCT05995769 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2024-05-07

No results posted yet for this study

Summary

The aim of this study is to determine if a single dose of psilocybin administered with motivational enhancement therapy (MET) can reduce heavy drinking in patients with an alcohol use disorder (AUD).

Conditions

Interventions

DRUG

Psilocybin

Single dosing session followed by 5 MET weekly sessions starting 24hrs after dosing

Sponsors & Collaborators

  • Johns Hopkins University

    collaborator OTHER

  • University of Maryland

    collaborator OTHER

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • University of Calgary

    lead OTHER

Principal Investigators

  • Leah Mayo, PhD · University of Calgary

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
22 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-20
Primary Completion
2027-10-01
Completion
2027-10-01

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05995769 on ClinicalTrials.gov